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TO THE EDITOR
Fibronectins (FNs) are high molecular
weight glycoproteins present in
extracellular connective tissue matrices
(ECM) and extracellular ﬂuids, includ-
ing blood plasma. The human FN gene
consists of 45 exons, and the pri-
mary mRNA transcripts are alternatively
spliced to form up to 20 different mRNA
variants (White et al., 2008). The
FNs interact with other matrix
macromolecules, such as collagens,
glycosaminoglycans, and ﬁbrin, as well
as cell surface receptors, including
Table 2. FLG genotyping results for patients of white European ethnicity
Cases, n (%) Controls, n (%)
Comorbid atopic disease 22 (44.9) Undetermined
FLG wild-type genotype 38 (77.6) 88 (88.0)
FLG heterozygote genotype 10 (20.4) 12 (12.0)
FLG homozygote or compound heterozygote 0 0
Incomplete genotyping data 1 (2.0) 0
Total 49 (100.0) 100 (100.0)
χ2 analysis P=0.16
Odds ratio (95% CI) 1.92 (0.77–4.85)
Abbreviations: CI, conﬁdence interval; FLG, ﬁlaggrin.
Cases with Fitzpatrick skin type of IV–VI were excluded from the genetic analysis because FLG loss-of-
function mutations remain ill deﬁned in these ethnic groups.
See related commentary on pg 1714
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Abbreviations: cFN, cellular ﬁbronectin; ECM, extracellular matrix; EDA, extra domain A; FN, ﬁbronectin;
PBS, phosphate-buffered saline; TGF-β, transforming growth factor-β; TLR4, toll-like receptor 4; WT,
wild type
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integrins α9β1, α5β1, and αvβ3, and toll-
like receptor 4 (TLR4; Charo et al., 1990;
Okamura et al., 2001). The precise role
of individual isoforms of FN in ECM
biology and pathology remains unclear.
One of the alternatively spliced exons
encodes the extra domain A (EDA), also
known as extra type III repeat, that is
regulated developmentally and is found
exclusively in cellular FN (cFN) but not
in plasma FN (Muro et al., 1999). The
latter form is synthesized by hepatocytes
and secreted into the circulation,
whereas cFN is produced by a variety
of cells, including ﬁbroblasts and epi-
thelial cells, and is deposited as ﬁbrils in
the ECM.
The in vivo role of the EDA variant
has been studied by constructing
mouse strains either constitutively
expressing (FN-EDA+/+) or excluding it
(FN-EDA− /− ; Muro et al., 2003). No
embryonic lethality or postnatal mal-
formations were observed in the case of
the homozygous mutant FN-EDA− /−
mice, suggesting that EDA is not
required for normal development. How-
ever, signiﬁcant abnormalities were
observed in adult FN-EDA− /− animals.
Speciﬁcally, the EDA peptide segment
is not found in the skin of wild-type
(WT) animals, but FN-EDA was shown
to be essential for normal wound
healing, particularly with respect to
re-epithelization. Although wound heal-
ing in EDA+/+ mice was indistinguish-
able from EDAwt/wt mice, the wounds
in FN-EDA− /− mice showed ulcerations
in the epidermis resulting in delay of
re-epithelialization. Furthermore, both
FN-EDA+/+ and FN-EDA− /− mice had
shortened life spans compared with
WT animals.
Compelling recent evidence has
accumulated implicating a crucial role
for FN-EDA not only in normal wound
healing but also in ﬁbroproliferative
disorders characterized by increased
production and deposition of ECM.
Treatment of normal ﬁbroblasts with
transforming growth factor-β (TGF-β), a
critical cytokine in the pathogenesis of a
variety of ﬁbroproliferative disorders,
results in a substantial increase in FN-
EDA production (Balza et al., 1988;
Chalmers, 2011). Interestingly, FN-EDA
upregulation precedes that of collagen,
and FN-EDA is required for the induct-
ion of the myoﬁbroblastic phenotype by
TGF-β. Furthermore, FN-EDA-null mice
failed to develop signiﬁcant lung ﬁbro-
sis after bleomycin administration
(Muro et al., 2003). Recently, Varga
and co-workers (Bhattacharyya et al.,
2014) demonstrated increased FN-EDA
in the skin and circulation of patients
with scleroderma. In addition, exogen-
ous FN-EDA potently stimulated col-
lagen production and myoﬁbroblast
differentiation in vitro, which was
mediated by TLR4. These observations
stimulated our investigation of the role
of FN-EDA in the development of
keloids, an abnormal ﬁbroproliferative
response
elicited by trauma to the skin of
genetically susceptible individuals; the
pathogenesis of this disorder remains
obscure (Bran et al., 2009). Our results
suggest that FN-EDA may have a critical
role in the keloid disease process.
Discarded tissue specimens were
obtained anonymously from patients
undergoing cosmetic surgical excision
of keloids and from patients undergoing
panniculectomy (for patient information,
see Supplementary Table S1 online). The
use of discarded tissue was approved
by the Institutional Review Board of
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Figure 1. Expression of FN-EDA in keloid tissues. Note 70-fold increase in mRNA levels in keloid tissue versus control (n= 5 for both groups; mean± SE;
P= 0.005851). (a) Western blot results for tissue protein isolates from three keloid samples and three control samples (b). A total of 20 μg protein was loaded into
each well; the presence of ﬁbronectin-EDA (220 kD) is demonstrated in keloid extracts versus near total absence in controls. Expression was normailzed in each
sample to β-actin levels present in each protein isolate (42 kD). Immunoﬂuorescence of frozen sections of keloid (c, left and d; scale bar = 30 μm) and control
skin (c, right). Note the heavy decoration of the surfaces of the type III collagen ﬁbers (shown in red) with FN-EDA antibody (shown in green) in keloids in contrast
to a complete absence of FN-EDA in control skin (c, right). EDA, extra domain A; FN, ﬁbronectin.
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were dissected, sterilized with betadine
solution, subcutaneous adipose tissue
was removed, and the samples were
prepared for gene expression analysis.
Total RNA was extracted from all speci-
mens using the RNeasy Kit (Fibrous
Tissue Kit, Qiagen, Alameda, CA) and
reverse transcribed to cDNA. Primer
pairs were designed to amplify FN-EDA
gene sequences as well as the house-
keeping gene, glyceraldehyde-3-phos-
phodehydrogenase, as a control (for
primer sequence information, see
Supplementary Table S2 online). Rela-
tive quantitative RT-PCR was performed
to investigate the expression of total
FN, as well as FN-EDA in both keloid
and control specimens. As demon-
strated previously (Kischer and Hendrix,
1983; Sible et al., 1994), the total FN
expression was increased in keloids
by 10.7-fold over controls. However,
the results indicated a signiﬁcant, up to
70-fold (P=0.005851), increase in FN-
EDA mRNA in keloid tissues in compa-
rison to controls (n=5 both groups;
Figure 1a). Thus, the relative increase
in cFN-EDA in comparison to total FN
was ~7-fold higher in keloids.
To investigate whether the increased
mRNA transcript levels result in simi-
larly increased protein levels in keloid
tissues, total protein was extracted
from keloids and control tissue speci-
mens via bead-mill homogenization
in the presence of protein lysis buffer
containing Radio-Immunoprecipitation
Assay Buffer (RIPA) buffer, phenyl-
methylsulfonyl Fluoride (PMSF), and
EDTA-free protease inhibitor cocktail
(Roche Diagnostics, Indianapolis, IN).
20 μg of total protein from each sample
was subjected to SDS/PAGE (4–20%
gel) in the presence of reducing agent.
Protein was electrotransferred to poly-
vinylidene ﬂuoride membrane, and
nonspeciﬁc binding sites on the mem-
brane were blocked by incubation in
5% milk for 1 hour at room tempera-
ture. The blot was incubated with
anti-FN EDA antibody (IST-9) in
1:200 dilution overnight at 4 °C and
anti-β actin primary antibody (ab8224,
Abcam, Cambridge, MA) and then
incubated with Licor 800cw infrared
anti-mouse secondary antibody at
1:5,000 dilution for 1 hour at room
temperature. After several washings, the
signal was determined with Odyssey
infrared image scanner (LiCor Biotech-
nology, Lincoln, NE).
Western blotting of the protein from
keloids, as illustrated in Figure 1b,
revealed a signiﬁcantly enhanced level
of FN-EDA of the molecular weight
of ~ 220 kDa, corresponding to a FN
monomer, whereas very little, if any,
protein was found in extracts of control
specimens. Localization of FN-EDA
in keloid tissues was determined
by immunoﬂuorescence staining with
the same antibody (IST-9 monoclonal
hybridoma supernatant, undiluted) as
used for western blotting, recognizing a
10-amino acid peptide sequence within
the EDA segment, and an antibody
to type III collagen (Rockland No. 600-
401-105-0.1), overnight at 4 °C follo-
wed by 3 washes in phosphate-buffered
saline (PBS). Sections were incubated
for 1 hour at room temperature with
1:200 dilutions in PBS of Alexa Fluor
488 goat anti-mouse and Alexa Fluor
594 goat anti-rabbit secondary anti-
bodies (Invitrogen, Grand Island, NY).
After 3 washes in PBS, sections were
then incubated at room temperature for
15 minutes with a 1:1,000 dilution of
DAPI in PBS (Southern Biotech, Bir-
mingham, AL). After washing 3X with
PBS, sections were mounted in Fluoro-
mount G (Southern Biotech) and visua-
lized. The results indicated intense
staining of FN-EDA in association with
broad collagen ﬁbers within the keloids,
as visualized by anti-type III collagen
antibody, whereas little, if any, staining
was noted in control skin (Figure 1c
and d). Thus, the keloidal lesions
contain an abundance of FN-EDA.
Although total FN expression has been
shown to be higher in keloid ﬁbroblasts
compared with control dermal ﬁbro-
blasts (Kischer and Hendrix, 1983; Sible
et al., 1994), the high level of FN-EDA
expression in keloid tissue has not
been previously reported. Although the
mechanisms of the high level of FN-EDA
expression in keloid tissue and its virtual
absence in normal tissue remain to be
determined, its presence may explain in
part the continuous excess matrix pro-
duction. EDA acting through the TLR4
receptor may enhance the activation of
ﬁbroblasts, resulting in increased produc-
tion of TGF-β and subsequent production
and accumulation of ECM molecules,
particularly collagen, creating a positive
feedback loop, thus establishing progres-
sive ﬁbrosis. This hypothesis suggests
that blocking FN-EDA synthesis or its
interactions with cell surface receptors
may provide suitable strategies to inter-
rupt the ﬁbrotic reaction in keloids.
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